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A B S T R A C T
Introduction: Failure to predict drug-induced liver injury (DILI) remains a major contributing factor to lead
compound drop-out during drug development. Xenopus embryos are amenable for early stage medium
throughput small molecule screens and so have the potential to be used in pre-clinical screens. To begin to assess
the usefulness and limitations of Xenopus embryos for safety assessment in the early phases of drug development,
paracetamol was used as a model hepatotoxin. Paracetamol overdose is associated with acute liver injury. In
mammals, the main mechanism of paracetamol-induced acute liver injury is an increased amount of the reactive
metabolite N-acetyl-p-benzoquinone imine (NAPQI) combined with a reduction of free glutathione (GSH).
Humans that have taken an overdose of paracetamol are often treated with N-acetyl cysteine (NAC).
Method: Xenopus laevis embryos were treated with up to 5mM paracetamol from stage 38 to stage 45 during
development, when the liver is functional. The presence of paracetamol-induced liver injury was assessed by: (1)
microRNA-122 (miR-122) expression (a hepatic marker), (2) free GSH concentration (a marker of oxidative
stress) and (3) NAC antioxidant intervention.
Results: The amount of free GSH decreased significantly in embryos exposed to increasing paracetamol con-
centration. In embryos exposed to 5mM paracetamol, 22.57 ± 4.25 nmol/mg GSH was detected compared to
47.11 ± 7.31 nmol/mg untreated embryos (mean ± SEM). In tail tissue, miRNA-122 expression increased 6.3-
fold with 3mM paracetamol concentration treatment compared to untreated embryos. NAC treatment altered
the free GSH decline for embryos treated with up to 5mM. Embryos exposed to 1mM paracetamol and then
exposed to 0.5mM NAC 24 h prior to harvest, had a significantly higher amount of GSH compared to embryos
that were only exposed to 1mM paracetamol (mean ± SEM; 97.1 ± 9.6 nmol/mg and 54.5 ± 6.6 nmol/mg
respectively).
Conclusion: Xenopus laevis embryos exhibit similar characteristics of paracetamol-induced liver injury observed
in mammalian models. These data indicate that the Xenopus embryo could be a useful in vivomodel to assess DILI
and aid lead compound prioritisation during the early phase of drug development, in combination with pre-
clinical in vitro studies. Consequently, the Xenopus embryo could contribute to the reduction principle as defined
by the National Centre for the Replacement, Refinement and Reduction of Animals in Research.
1. Introduction
Paracetamol is a frequently used antipyretic and analgesic drug that
is safe at the therapeutic dose, which is 4 g/day. However, it exhibits
dose-dependent hepatotoxicity and severe liver injury can occur when a
single dose of 10–15 g of paracetamol is taken (Dart et al., 2006;
Jaeschke, 2015). Paracetamol contributes to 80% of the liver failure
cases associated with drugs (Larson et al., 2005). It is the single largest
cause of acute liver failure in the US and the UK and the second most
common reason for a liver transplant (Ostapowicz et al., 2002). In the
UK, it is estimated approximately 90,000 patients present with para-
cetamol overdose a year, resulting in 50,000 hospital admissions and
150–250 deaths (Bateman et al., 2014; Wong et al., 2014; Hawton
et al., 2013). The paracetamol reactive metabolite that is responsible
for paracetamol-induced liver injury is N-acetyl-p benzoquinone imine
(NAPQI). When a paracetamol overdose has been taken, the supply of
cellular glutathione (GSH) is saturated and therefore less NAPQI is
neutralised. In hepatocytes, NAPQI can form protein adducts with in-
tracellular proteins, which can lead to mitochondrial dysfunction, nu-
clear DNA fragmentation, oxidative stress, hepatocyte death and sub-
sequent acute liver failure, and potentially patient death (Prescott,
1980; Jaeschke et al., 2012). The major cell death pathway is necrotic,
although some apoptotic cell death can also occur.
Xenopus laevis (the African clawed frog) can produce approximately
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1000 embryos/day with hormonal stimulation. Following in vitro fer-
tilisation, the embryos rapidly develop ex utero and are amenable for
medium throughput small molecule screens. As part of these screens, it
was noted that Xenopus embryos could highlight compound toxicity
(Tomlinson et al., 2012, 2005, 2009). Consequently, as well as being
useful to identify new drugs, Xenopus embryos may also represent a
model for early phase pre-clinical drug toxicity studies during drug
development. Previously, we have successfully used this model to help
assess nanotoxicity for biomedically-relevant nanomaterials (Webster
et al., 2016).
The Xenopus embryo shares similar advantages to another non-
mammalian animal model, the zebrafish (Danio rerio) (Wheeler and
Brändli, 2009). They are both easier to house and less expensive than
mammalian animal models. However, unlike in zebrafish, not much
work has been done to investigate the use of Xenopus embryos for the
prediction of drug-induced toxicity.
Drug-induced liver injury (DILI) was investigated in order to begin
to characterise the use of Xenopus embryos as a predictive tool for drug-
induced toxicity. Paracetamol was used as the model hepatotoxin.
Paracetamol-induced liver injury is dose-dependent. Therefore it was
hypothesised that the Xenopus laevis embryos would exhibit indications
of paracetamol-induced liver injury that correlated with paracetamol
dose exposure. Increasing paracetamol concentration exposure to the
Xenopus embryos, correlated with an increased expression of the liver-
specific biomarker miR-122 in tissue that does not include the liver, and
a depletion of free GSH.
2. Methods
All experiments were performed in compliance with the relevant
laws and institutional guidelines at the University of East Anglia. This
research has been approved by the local ethical review committee ac-
cording to UK Home Office regulations. Xenopus embryo stages were
identified according to Nieuwkoop and Faber (1994).
Xenopus laevis embryos develop at a rate that is proportional to the
temperature at which they are incubated. Consequently, unlike the
zebrafish, the age of a Xenopus embryo cannot be given in hours post
fertilisation (hpf), instead, the age can be identified using the devel-
opmental stages set out by Nieuwkoop and Faber (these can also be
found on the NIH-funded website xenbase.org) (Nieuwkoop and Faber,
1994). At 25 °C, a Xenopus embryo can develop into an adult in 12
months, this is the temperature that elicits the fastest development rate.
At< 12 °C the embryos will die however, between 12 °C and 25 °C, the
embryos will develop at a rate proportional to the temperature. An
incubation temperature of 23 °C was used for all of the following ex-
periments.
2.1. Embryo fixing
Once the embryos reached their desired stage they were fixed using
MEMFA (3.7% (v/v) formaldehyde, 1X MEM salts (0.1 M MOPS, 2mM
EGTA, 1mM MgSO4, pH7.4) made up with dH2O. They were then
dehydrated in 100% ethanol (EtOH) and stored at −20 °C.
2.2. RNA isolation and cDNA synthesis
After incubation until the stage required, 10 embryos were frozen in
liquid nitrogen for at least 2 h. mRNA was isolated using the trizol
method, miRNA was isolated using the miRCURY™ RNA Isolation (for
tissue) kit according to manufacturer’s instructions. For miRNA, cDNA
was generated using the Universal cDNA synthesis kit II (Exiqon).
2.3. qRT-PCR
The reaction was performed in MicroAmp optical 96 well plate
(Applied Biosystems)., miRCURY™ LNA PCR Primer mix (Exiqon) or
10 μM MRP2 primer and SYBR® Green PCR Master Mix (Applied
Biosystems). A 7500 real-time PCR instrument (Applied Biosystems)
was used under the following conditions. Samples were plated in tri-
plicates (technical replicates). Samples derived from embryos produced
from different mothers were the biological replicates.
2.4. Wholemount in situ hybridisation (WISH)
DIG labelled probes were synthetised with a Digoxigenin (DIG) la-
beled UTPs (Roche) and purified using Illustra MicroSpin G-50 Columns
(GE healthcare life sciences) according to manufacturer’s instructions.
Micro-RNA probes were obtained from Exiqon. WISH was carried out as
previously described (Ahmed et al., 2015; Harrison et al., 2004)
2.5. Paracetamol treatment
Paracetamol (Sigma, UK) was dissolved in 0.1X MMR alone. Embryo
age was determined according to Nieuwkoop and Faber (1994). For 1
biological replicate (n= 1), we used 7 embryos for each drug con-
centration. Consequently 5 biological replicates (n=5) used a total of
35 embryos. 1 biological replicate is defined as using 1 adult frog
mother. In other words, a result generated from embryos that have the
same mother, was only counted as 1 biological replicate.
2.6. The preparation of samples for the measurement of miR-122 expression
using qRT-PCR
Stage 38 embryos were treated with paracetamol as described above
until stage 45. At stage 45, the embryos put into 0.5mg/mL tricaine
(0.1X MMR) and incubated at 23 °C for 1 h. Embryos were dissected
into tail and gut tissue using a simple razor blade. The dissection
technique was confirmed by analyzing the expression of the liver-spe-
cific marker AMBP. AMBP was expressed in the gut tissue dissected but
not in the tail tissue.
2.7. N-acetyl cysteine (NAC) and paracetamol
2.7.1. Pre-incubation
Stage 38 embryos were exposed to a final concentration of 0.5 mM
NAC at 23 °C for 2 h prior to paracetamol. This was incubated for a
further 70 h, until the embryos were stage 45 at 23 °C. The embryos
were processed with the GSH assay method.
2.7.2. Concurrent treatment
Stage 38 embryos were exposed to a final concentration of 0.5 mM
NAC and a paracetamol concentration within the range 0–5mM para-
cetamol at 23 °C for 72 h until the embryos were stage 45. The embryos
were processed with the GSH assay method.
2.7.3. 24 h NAC treatment prior to harvest
Stage 38 embryos were exposed to paracetamol within the range
0–5 mM at 23 °C for 48 h. At 48 h we added NAC to a final con-
centration of 0.5mM and this was further incubated for 24 h at 23 °C
until the embryos were stage 45.
All the embryos were processed with the GSH assay method at stage
45.
2.8. Measuring free GSH
2.8.1. Sample preparation
At the end of the incubation period, embryos that were treated with
the same conditions were pooled. As much as possible, the incubation
solution was removed and the embryos were homogenized. The amount
of free GSH was measured in the supernatant using a GloMax® Explorer
System spectrophotometer (Promega) and quantified using the
Bradford assay.
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Fig. 1. Paracetamol exposure dose-response phenotype.
Xenopus laevis embryos were exposed to a paracetamol concentration in the range 0–5mM (n=4). The embryos were exposed to paracetamol from stage 38 and
harvested at stage 45. Phenotypes include wildtype (A), damaged tail (B), oedema (C), abnormal gut (D) and bent tail (E). The surviving embryos at stage 45 were
photographed and the different phenotypes found for each paracetamol concentration were calculated as a percentage of total embryos tested (F). Where possible, the
embryos were photographed to show the lateral view and the ventral view. Scale bar represents 1mm.
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2.9. Statistical analysis
Statistical tests were carried out using GraphPad Prism 6.0 software.
An ordinary one-way ANOVA was used for investigating the difference
of the treated groups compared to the untreated embryos and Mann-
Whitney non-parametric tests were used to compare unpaired treat-
ment groups.
3. Results
3.1. Paracetamol exposure response in Xenopus laevis embryos
Stage 38 Xenopus laevis embryos were exposed to paracetamol that
was dissolved into the embryo incubation media. After a 72 h incuba-
tion period, the resulting stage 45 embryos showed a variety of phe-
notypes (Fig. 1). Untreated stage 45 Xenopus embryos were termed
“wildtype”. In the treatment group, the wildtype phenotype was less
common with increasing paracetamol concentration. Of the embryos
that were exposed to the Xenopusmedia only, 96% displayed a wildtype
phenotype, which decreased to 24% for the embryos exposed to 5mM
paracetamol.
Phenotypes that deviated from the norm included damaged tail,
oedema, abnormal gut and bent tail (Fig. 1A–E). The incidence of all
phenotypes that are different to the wildtype was larger with increasing
paracetamol concentration from 4% to 46%, Xenopus media only to
5mM paracetamol exposure respectively (Fig. 1F). Oedema typically
occurred around the gastro-intestinal region of the embryo (Fig. 1C).
The percentage of stage 38 embryos that were exposed to 5mM para-
cetamol and did not survive to the harvest age of stage 45 was 9%
compared to the 4% incidence for the embryos exposed to Xenopus
media only.
3.2. Free GSH content in paracetamol treated embryos
In humans, the generation of the reactive metabolite, NAPQI, and
the reduction of the neutralising agent, GSH, mediate paracetamol-in-
duced liver injury. Consequently, the amount of free GSH can indicate
the metabolism pathway of paracetamol and be an indirect measure-
ment of paracetamol-induced liver injury. Existing in vivo or in vitro
assays that imitate human paracetamol overdose and the associated
acute liver failure, show a reduction of free GSH in the assay system
(Howell et al., 2014; Shenton et al., 2004; Goldring et al., 2004;
Vliegenthart et al., 2017).
Embryos at stage 38 were treated with a paracetamol concentration
within the range 0–5mM, harvested at stage 45, and processed to
measure the amount of free GSH (n= 10) (Fig. 2). The amount of free
GSH decreased from 47 nmol/mg to 22 nmol/mg with increasing con-
centration of paracetamol (0–5mM). Embryos treated with a para-
cetamol concentration within the range 3–5mM had statistically sig-
nificantly less free GSH compared to untreated embryos (5mM
paracetamol exposure mean ± SEM was 22.57 ± 4.25 nmol/mg
compared to untreated mean ± SEM of 47.11 ± 7.31 nmol/mg). Xe-
nopus laevis embryos that are incubated at 23 °C take 72 h to develop
from stage 38 to stage 45. In order to explore the time-dependency of
the decline in free GSH, stage 38 embryos were treated with the same
paracetamol concentration range (0–5mM) and harvested after 24 h, at
stage 41 (Fig. 2B). There was no significant change in the relationship
between paracetamol treatment and amount of free GSH when the
embryos are treated for 24 h.
3.3. miR-122 is a marker for the liver in Xenopus embryos
The location of the liver is not always obvious in the Xenopus laevis
embryo, it is< 0.5mm at its widest diameter, and the colour of it is not
notably different to the intestines. Thus, a probe was used to identify
the liver using a wholemount in situ hybridisation (WISH) protocol.
Alpha-1-microglobulin/bikunin precursor (AMBP) is a protein specifi-
cally expressed in the Xenopus liver (Zorn and Mason, 2001) and so it
was used as a positive control for the WISH. Stage 38 and stage 45
embryos expressed AMBP in the presumed location of the liver (Fig. 3A)
(n= 10).
The expression of miR-122 in the Xenopus embryos was investigated
using the WISH assay (Ahmed et al., 2015) (Fig. 3B) (n=10). MiR-122
expression is specific to the liver in humans as well as rodent and
zebrafish animal models (Starkey Lewis et al., 2011; Vliegenthart et al.,
2015; Antoine et al., 2013). Elevated miR-122 in the circulation can
therefore serve as a biomarker for DILI (Wang et al., 2009). The miR-
122 WISH probe has been extensively characterised in Xenopus pre-
viously (Ahmed et al., 2015). The WISH for miR-122 stained the same
area as AMBP in stage 38 and stage 45 embryos (Fig. 3). Therefore, it
was concluded that the miR-122 expression in Xenopus laevis is specific
to the liver tissue, which is very similar to the expression seen in rodent,
zebrafish and humans.
3.4. The expression of miR-122 in the different tissues of embryos treated
with paracetamol
Stage 38 embryos were exposed to a paracetamol concentration
within the range 0–5mM, harvested at stage 45 and then processed to
measure the expression of miR-122 using qRT-PCR. Embryos were
dissected to obtain gut tissue that included the liver and tail tissue to
represent the blood. The tail contains a good vasculature and the liver
tissue is not present in this body compartment (Supplementary Fig. 1).
The miR-122 expression levels were normalised to a miRNA (miR-
103), which has been shown to not be affected by paracetamol treat-
ment in rodents (Wang et al., 2013). Similarly, the expression of miR-
103 is not affected by paracetamol in Xenopus laevis (Supplementary
Fig. 2). The miR-122 expression was also normalised to untreated
(Xenopus media only) embryos (Fig. 4).
The expression of miR-122 increased in the tail tissue with in-
creasing paracetamol concentration. In untreated wildtype embryos,
the miR-122 expression in the tail was minimal. miR-122 expression in
the tail of embryos treated with 3mM and 4mM paracetamol was
significantly different compared with miR-122 expression in the gut
tissue from the same paracetomol-treated embryos (Fig. 4). Embryos
treated with the 3mM paracetamol concentration in particular, had a
6.3-fold (plotted as 0.8 on the logarithmic y-axis scale) increase in miR-
122 expression in the tail, compared with the tail tissue of untreated
embryos. In the gut tissue, the expression of miR-122 appears to be
slightly reduced in treated embryos compared with untreated embryos,
but miR-122 expression does not change in relation to the paracetamol
concentration, it remains level (Fig. 4).
3.5. Treatment with acetyl-meta-aminophenol (AMAP)
AMAP is supposedly the non-toxic regioisomer version of APAP, but
this appears to be species-dependent (Hadi et al., 2013). The Xenopus
response to AMAP was explored by looking at the effect of GSH de-
pletion, which was determined by measuring the amount of free GSH in
embryos from the same mother, treated with either AMAP or APAP in
the same concentration range (0–5mM, n= 3). The embryos treated
with AMAP produced a negative correlation: as the concentration of
AMAP increased, the amount of free GSH detected decreased (Fig. 5).
The amount of GSH between embryos treated with the same con-
centration of either AMAP or APAP was not significantly different.
3.6. Xenopus incubation with the human clinical treatment for paracetamol
overdose
In the clinic, patients are administered N-acetyl cysteine (NAC) to
prevent severe paracetamol-induced liver injury. The NAC replenishes
GSH stores, scavenges ROS in mitochondria and enhances the
K. Saide et al. Toxicology Letters 302 (2019) 83–91
86
sulphation APAP metabolic pathway. The NAC therapeutic effect is
more useful at preventing liver injury if it is taken less than 8 h after the
APAP overdose (Waring, 2012; Smilkstein et al., 1988).
Xenopus embryos were co-incubated with 0.5mM NAC and a con-
centration within the 0–5mM APAP range. Initially, NAC and APAP
were co-incubated in 2 conditions: (Dart et al., 2006) incubation of the
stage 38 embryos with 0.5mM NAC for 2 h and then the APAP con-
centration was added to the media and (Jaeschke, 2015) concurrent
0.5 mM NAC and APAP (n= 10) (Fig. 6A). The embryos were harvested
at stage 45 and compared to embryos treated with APAP alone. The free
GSH concentration was measured and normalised to the untreated
embryos for each condition, which are denoted as a percentage of the
0mM treatment group. Embryos treated with NAC alone did not have a
significantly different amount of free GSH to the untreated wildtype
embryo. Embryos that were pre-incubated with NAC before the APAP
addition, had a decrease in free GSH with increasing APAP concentra-
tion, however the gradient was smaller in comparison to their coun-
terparts that were treated with APAP only (Fig. 6A). The concurrent
NAC and APAP co-incubation also had a negative correlation between
free GSH and APAP concentration, but this gradient was (on average),
smaller than the pre-incubation treatment. Both methods showed a
trend where NAC reduced the effect of APAP on GSH, but this was not
statistically significant.
Next, 0.5 mM NAC was added to APAP-treated embryos 24 h, prior
to their harvest at stage 45 (n=5) (Fig. 6B). The free GSH measured in
the embryos treated with NAC was (on average), higher than the
counterpart embryos treated with the same APAP concentration com-
pared with APAP alone. However, the amount of free GSH measured in
NAC-treated embryos did decrease with increasing APAP concentration,
though significantly less than in embryos treated with APAP alone.
Fig. 2. The amount of free GSH inside Xenopus embryos
treated with paracetamol.
Xenopus laevis embryos were exposed to 0–5mM para-
cetamol from the age of stage 38, and harvested at stage 45
(A, n= 10) or at stage 41 (B, n=3). The amount of free
GSH (nmol/mL) was measured inside the embryos and
normalised to the amount of protein (mg/mL). An ordinary
one-way ANOVA compared each exposure group to the
group exposed to Xenopus media alone (0mM). For the
embryos exposed until stage 45 (A), the amount of free
GSH for 3, 3.5, 4 and 4.5mM paracetamol exposure groups
was statistically significant compared to the group exposed
to Xenopus media only (P < 0.05). The 5mM paracetamol
exposure group was also statistically significantly different
(P < 0.01). There was no significant difference between
treated and untreated embryos that were harvested at
stage 41 (B).
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4. Discussion
To our knowledge, the Xenopus laevis animal model has not been
thoroughly assessed as a model to predict drug-induced toxicity. To
begin to investigate the usefulness and limitations of Xenopus laevis
embryos in this area, this research focused on the response to one
known hepatotoxic drug, paracetamol. The results generated here
suggest that Xenopus could be a suitable model to predict DILI.
The Xenopus liver has the same cell types as found in humans in-
cluding hepatocytes, stellate cells, Kupffer cells and sinusoidal en-
dothelial cells (Blitz et al., 2006). Similar to vertebrates, the liver is
derived from the endoderm of the future gut tube, close to where the
stomach and duodenum will meet (Nieuwkoop and Faber, 1994). By
tadpole stage 37–39, the Xenopus liver is a sac-like structure, with thick
walls that fold inwards and fills the liver cavity with hepatocytes. Also
at this time, the liver and biliary ductal systems are developing and the
gall bladder is a thin-walled sac structure (Blitz et al., 2006). At late
stage development (stage 38–45) the Xenopus heart, liver and kidney
Fig. 3. Wholemount in situ hybridisation (WISH) for liver markers.
WISH assay for Alpha-1-Microgobulin/Bikunin Precursor (AMBP) (A) and miR-122 (B) at stage 38 (Ai and Bi) and stage 45 (Aii and Bii). The stage 38 embryos are
shown in lateral view and the stage 45 embryos are shown ventrally. The specific purple WISH stain is indicated with an arrow. These embryos are representatives of
the typical expression patterns seen (n= 10). Scale bar represents 1 mm.
Fig. 4. Expression of miR-122 in paracetamol-treated embryos.
Stage 38 embryos were exposed to paracetamol (0–5mM) and harvested at
stage 45. The expression of miR-122 in the gut (purple) and tail (red) was
measured using qRT-PCR (log (fold change ± SEM)) and normalised to em-
bryos exposed to Xenopus media only (0mM). The statistically significant dif-
ference of miR-122 expression between tissues from embryos treated with the
same paracetamol concentration was measured using the Mann-Whitney test
(P < 0.05) (n= 5).
Fig. 5. The amount of free GSH inside Xenopus embryos treated with para-
cetamol (APAP) or N-acetyl-meta-aminophenol (AMAP).
Xenopus laevis embryos were exposed to up to 5mM paracetamol (APAP) or up
to 5mM N-acetyl-meta-aminophenol (AMAP) from the age of stage 38 and
harvested at stage 45 (n= 3). The amount of free GSH (nmol/mL) was mea-
sured inside the embryos and normalised to the amount of protein (mg/mL).
There was no significant difference between embryos treated with the same
concentration of APAP and AMAP.
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are functional and adding compounds at this stage would assess drug-
induced toxicity. Of the key enzymes involved in paracetamol meta-
bolism in humans, the Xenopus enzymes of the same name are also
expressed at stage 38 and stage 45. Including the cytochrome P450
isoform CYP2E1, glutathione S-transferase (GST) isoforms P1, M1 and
T1, sulphotransferase (SULT) isoforms 1A1 and 2A1 and uridine 5′-di-
phospho-glucuronosyltransferase (UGT) 1A6 and 1A1 (Supplementary
Fig. 3).
It was hypothesised that toxicity assessment using the Xenopus
embryos in combination with existing in vitro pharmacological cyto-
toxicity profiling and mathematical modelling can provide early in vivo
testing without the need for extensive early mammalian testing. This
will be consistent with the reduction ideology of the National Centre for
the Replacement, Refinement and Reduction of Animals in research
(NC3R). Experiments using Xenopus could help prioritise the lead
compounds and provide more information than in vitro safety tests. This
would flag problem compounds before they enter pre-clinical testing in
rodents.
4.1. Phenotype and GSH
The paracetamol concentration range 0–5mM is consistent with the
dose used to investigate paracetamol-induced liver injury in zebrafish
in the literature. Furthermore, the gastrointestinal oedema phenotype
in the Xenopus embryos was also observed in response to paracetamol in
zebrafish larvae (Verstraelen et al., 2016). Similar to the Xenopus em-
bryos, zebrafish larvae were exposed to soluble paracetamol in the
media the embryos were swimming in. Furthermore, the zebrafish used
Fig. 6. Free GSH in embryos treated with paracetamol and
N-acetyl cysteine (NAC).
Stage 38 embryos were exposed to paracetamol (up to
5mM) for 72 h with or without the addition of 0.5mM
NAC, they were harvested at stage 45. For the initial ex-
periments (A) there were 3 conditions: exposure to para-
cetamol alone (blue), 2 h incubation with NAC prior to the
addition of paracetamol (pink) and concurrent treatment
with NAC and paracetamol (yellow) (n= 10). The em-
bryos were also exposed to APAP from stage 38 and then
with NAC for 24 h prior to harvest (green) at stage 45, a
72 h incubation period, or with paracetamol alone (blue)
(B) (n= 5). The amount of free GSH inside the embryos
was measured and normalised to the amount of protein.
This value was then normalised to the embryos exposed to
Xenopus media alone (0mM). The amount of free GSH
measured was calculated as a percentage of the 0mM
paracetamol exposure group (± SEM). A multiple com-
parison 2 way ANOVA was performed to measure the
statistical significance between groups of them same
paracetamol exposure, with and without additional NAC
exposure (P < 0.05).
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to model paracetamol-induced hepatotoxicity were aged of 72–120 hpf
which is close to the Xenopus embryo age used in the research presented
here (Verstraelen et al., 2016; He et al., 2013; Vliegenthart et al.,
2014a; North et al., 2010).
For paracetamol-induced liver injury in humans, the reduced
amount of free GSH is part of the pathophysiology mechanism as it
allows the accumulation of the reactive metabolite NAPQI. The re-
duction of free GSH observed in the Xenopus embryos (Fig. 2) implies
they have generated a small molecule from paracetamol, which de-
pletes the free GSH store. The absence of the reduction in the embryos
treated for only 24 h (Fig. 2B) indicates the GSH depletion could be
time-dependent. Or it could be that at stage 38, for the first 24 h of the
screen, the embryos do not have functional enzymes that are re-
sponsible for the production of the metabolites. The absence of meta-
bolite generation could explain why the amount of free GSH has not
been reduced. Future work should investigate the metabolic enzyme
activity involved with Xenopus paracetamol production. Our pre-
liminary work suggests that the embryos do generate similar para-
cetamol metabolites to humans (i.e. APAP-sulphate and APAP-glucur-
onide) (data not shown).
4.2. miR-122
Xenopus miR-122 has the same nucleotide sequence as zebrafish,
humans and rodents and the WISH results show that miR-122 is liver-
specific in the Xenopus, much like these animal models as well (Ahmed
et al., 2015; Wienholds et al., 2005; Vliegenthart et al., 2014b). The
presence of miR-122 in the blood in humans is an indication of DILI.
The Xenopus embryos have a circulatory system at the ages used in this
work, but the size of the embryos is too small to be able to easily obtain
a blood sample, and the volume of blood within the embryo is very
little. Consequently, in order to measure the expression of miR-122 with
paracetamol treatment, it was decided to use the tail tissue to represent
the blood or circulatory system. The tail contains a good vasculature
and the liver tissue is not present in this body compartment. Under
healthy circumstances there should not be a significant amount of miR-
122 expression found in the tail. The size of the embryos means dis-
secting the liver alone would be difficult and time consuming. There-
fore it was decided to dissect the whole gastrointestinal or gut region,
including the liver, to represent the liver miR-122 expression.
miR-122 expression was normalised against miR-103 expression in
the tissue of the embryos. Unlike U6, which is a small nuclear RNA
(snRNA) that is traditionally used for miRNA quantification in qPCR,
miR-103 is not affected by paracetamol treatment (Wang et al., 2013).
The increase of miR-122 expression in the tail with increasing para-
cetamol concentration in Fig. 4 implies paracetamol-induced liver in-
jury. This is comparable to adult zebrafish, which when exposed to a
hepatotoxic dose of paracetamol, have a significantly high serum miR-
122 expression (Vliegenthart et al., 2014b).The slight reduction of miR-
122 expression in RNA isolated from gut tissue is potentially indicative
of liver damage as fragmented WISH miR-122 staining in the liver in-
dicates hepatocyte injury. However, there is no linear trend of miR-122
expression in the gut with regards to paracetamol concentration. It is
hypothesised, this may be because miR-122 expression in the liver is so
abundant, that a slight depletion cannot be detected. For future work,
careful histological analysis of the liver to measure the presence of
paracetamol-induced liver necrosis would need to be carried out to
confirm this.
4.3. NAC
NAC is used to treat patients with a paracetamol overdose. Overall 3
incubation conditions were carried out with 0.5 mM NAC and 0–5mM
paracetamol: (Dart et al., 2006) 2 h NAC incubation prior to para-
cetamol addition, (Jaeschke, 2015) concurrent NAC and paracetamol
treatment, and (Larson et al., 2005) NAC incubation in paracetamol-
treated embryos for 24 h prior to harvest. Of the 3 conditions per-
formed, the 24 h incubation prior to harvest is the most clinically re-
levant to humans. Embryos exposed to 1mM paracetamol and then
exposed to 0.5 mM NAC 24 h prior to harvest, had a significantly higher
amount of GSH compared to embryos that were only exposed to 1mM
paracetamol (mean ± SEM; 97.1 ± 9.6 nmol/mg and
54.5 ± 6.6 nmol/mg respectively). However in all the treatment con-
ditions, the amount of free GSH measured is greater in the embryos of
the NAC treatment group compared with the embryos without NAC, of
the same paracetamol concentration group. This smaller decline of free
GSH with NAC treatment suggests the embryos are metabolising para-
cetamol to generate a small molecule that depletes GSH, and that this
pathway can be reversed through the administration of NAC. This
rescue mechanism implies (but cannot confirm) that the reactive me-
tabolite generated in the Xenopus embryos is NAPQI, the same reactive
metabolite produced in humans and other animal models.
The results are similar to the NAC response observed in zebrafish
paracetamol overdose. In adult zebrafish treated with paracetamol, the
amount of free GSH increased with NAC administration compared to
zebrafish treated with paracetamol alone (North et al., 2010). Overall,
these NAC response results indicate that Xenopus embryos are a pro-
mising model as they exhibit reactivity to human treatments.
4.4. AMAP: the non-toxic regioisomer of APAP
AMAP is a controversial, supposedly less toxic positional isomer to
paracetamol, which has similar therapeutic indications to paracetamol,
such as analgesic properties. In Xenopus embryos used here, the lack of
significant difference between AMAP and paracetamol for the depletion
of GSH indicates Xenopus could have a similar toxic reaction to AMAP
as paracetamol. The embryos also have a similar concentration-de-
pendent survival percentage for AMAP and paracetamol. This result
does not necessarily diminish the integrity of the Xenopus as a toxicity
prediction model, because toxicity associated with AMAP is not con-
sistent across the existing animal models in drug development (Hadi
et al., 2013).
5. Conclusion
Overall the Xenopus embryo model appears to have the ability to
react to paracetamol in a dose-dependent manner as shown by looking
at GSH levels and also by observing the expression of the liver-specific
biomarker miR-122 in the embryo. This is comparable to research un-
dertaken using zebrafish (Verstraelen et al., 2016; He et al., 2013;
Vliegenthart et al., 2014a; North et al., 2010). The depletion of GSH
with paracetamol treatment suggests the Xenopus embryo metabolic
pathway is similar to that observed in humans and rodent paracetamol-
induced liver injury models. To our knowledge, GSH reduction has not
been measured in the zebrafish paracetamol-induced hepatotoxicity
model. Going forward it would be interesting to confirm the mechanism
of toxicity using a CYP450 inhibitor that is valid for Xenopus. Further-
more, the CYP450 isoform that could be involved in the Xenopus me-
tabolism of paracetamol should be determined. Although the dominant
isoform in humans that generates the reactive metabolite NAPQI is the
CYP2E1, in zebrafish the CYP3 A65 isoform is predominantly re-
sponsible for NAPQI generation (Chng et al., 2012). At stage 38 to stage
45, the Xenopus embryos express CYP2D6 and CYP3 A4 as well as
CYP2E1. In humans CYP2D6 and CYP3 A4 are responsible for over 50%
of all drugs (Bertz and Granneman, 1997). In summary, these results
represent the initial steps towards determining the advantages and
limitations of the Xenopus embryo model as a predictive tool for DILI,
and pave the way for future assessment of the value of Xenopus as an
efficient and effective in vivo toxicity model for other organ systems.
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